Abstract
Thyroid dermopathy that occurs in 4–13 % of patients with Graves’ ophthalmopathy is an extrathyroidal manifestation of Graves’ disease. Thyroid acropachy commonly presents with clubbing of digits and occurs in 20 % of patients with dermopathy. Basic pathogenesis of dermopathy is similar to ophthalmopathy. Presence of TSH receptor in the fibroblasts and its interaction with TSH receptor antibodies and stimulation of fibroblasts resulting in production of glycosaminoglycans is the most likely immune process. Localization of thyroid dermopathy to lower extremity is explained by mechanical factors such as dependency of the lower extremity.
Measures for prevention and treatment of dermopathy include optimal and rapid normalization of thyroid function and early local corticosteroid therapy for existing pretibial myxedema. Systemic therapies used in ophthalmopathy can be tried in refractory cases not responding to local corticosteroid therapy. In future any systemic therapy proven to be beneficial for ophthalmopathy can be used empirically for refractory cases of dermopathy.
For thyroid acropachy no specific therapy has been reported and management should be preventive and local therapy for associated dermopathy of hands and feet. In severe cases of acropachy with painful periosteal reaction, pain management will be needed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Schwartz KM, Fatourechi V, Ahmed DD, Pond GR. Dermopathy of Graves’ disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab. 2002;87:438–46.
Rice SA, Peden NR, McGlynn S, Morton C. Atypical presentation of infiltrative thyroid dermopathy. Clin Exp Dermatol. 2010;35:56–8.
Pujol RM, Monmany J, Bague S, Alomar A. Graves’ disease presenting as localized myxoedematous infiltration in a smallpox vaccination scar. Clin Exp Dermatol. 2000;25:132–4.
Buljan-Cvijanovic M, Neal JM, Zemtsov A. Euthyroid pretibial myxedema. Endocr Pract. 1998;4:375–7.
Chen JJ, Ladenson PW. Euthyroid pretibial myxedema. Am J Med. 1987;82:318–20.
Jung Yuel H, Nack In K, Choong Rim H. A case of primary hypothyroidism associated with pretibial myxedema. Kor J Dermatol. 1993;31:408–11.
Stewart G, Rowland Payne CME, Croft DN. Hashimoto’s thyroiditis associated with dysthyroid eye disease, pretibial myxoedema and thyroid acropachy. J R Soc Med. 1984;77:240–3.
Sarkar D, Singh SK, Bandopadhyaya B, Kumar M, Agrawal JK. Hashimoto’s thyroiditis with ophthalmopathy and dermopathy. J Assoc Physicians India. 1997;45:331–2.
Iyer S, Bahn R. Immunopathogenesis of Graves’ ophthalmopathy: the role of the TSH receptor. Best Pract Res Clin Endocrinol Metab. 2012;26:281–9.
Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362:726–38.
Fatourechi V. Thyroid dermopathy and acropachy. Best Pract Res Clin Endocrinol Metab. 2012;26:553–65.
Davies TF. Trauma and pressure explain the clinical presentation of the Graves’ disease Triad. Thyroid. 2000;10:620–30.
Fatourechi V. Thyroid dermopathy and acropachy. Expert Rev Dermatol. 2011;6:75–90.
Fatourechi V, Ahmed DD, Schwartz KM. Thyroid acropachy report of 40 patients treated in a single institution in a 26-year period. J Clin Endocrinol Metab. 2002;87:5435–41.
Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121:284–90.
Fatourechi V, Garrity JA, Bartley GB, Bergstralh EJ, Gorman CA. Orbital decompression in Graves’ ophthalmopathy associated with pretibial myxedema. J Endocrinol Invest. 1993;16:433–7.
Ishizawa T, Sugiki H, Anzai S, Kondo S. Pretibial myxedema with Graves’ disease: a case report and review of Japanese literature. J Dermatol. 1998;25:264–8.
Lohiya S, Lohiya V, Stahl EJ. Pretibial myxedema without ophthalmopathy: an initial presentation of Graves’ disease. Am J Med Sci. 2013;346:73–5.
Bartley GB, Fatourechi V, Kadarmas EF, Jaconson SJ, Ilstrup DM, Garrity CA. Chronology of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121:426–34.
Chertman M, Assaf RR. An unusual case of pretibial myxedema following long-term treatment of graves’ disease. Thyroid. 2013;23:A41.
Georgala S, Katoulis AC, Georgala C, Katoulis EC, Hatziolou E, Stavrianeas NG. Pretibial myxedema as the initial manifestation of Graves’ disease. J Eur Acad Dermatol Venereol. 2002;16:380–3.
Cho S, Choi JH, Sung KJ, Moon KC, Koh JK. Graves’ disease presenting as elephantiasic pretibial myxedema and nodules of the hands. Int J Dermatol. 2001;40:276–7.
Omohundro C, Dijkstra JW, Camisa C, Bergfeld WF. Early onset pretibial myxedema in the absence of ophthalmopathy: a morphologic evolution. Cutis. 1996;58:211–4.
Cheung HS, Nimni ME, Kamiel MB, Nicoloff JT. Evidence for a fibroblast stimulating factor(s) in serum of patients with pretibial myxedema. Clin Res. 1977;25:A147.
Zhao P, Deng Y, Gu P, Wang Y, Zhou H, Hu Y, Chen P, Fan X. Insulin-like growth factor 1 promotes the proliferation and adipogenesis of orbital adipose-derived stromal cells in thyroid-associated ophthalmopathy. Exp Eye Res. 2013;107:65–73.
Smith TJ, Hegedus L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26:291–302.
Varewijck AJ, Boelen A, Lamberts SWJ, Fliers E, Hofland LJ, Wiersinga WM, Janssen J. Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2013;98:769–76.
Chang TC, Wu SL, Hsiao YL, Kuo ST, Chien LF, Kuo YF, Change CC, Chang TJ. TSH and TSH receptor antibody-binding sites in fibroblasts of pretibial myxedema are related to the extracellular domain of entire TSH receptor. Clin Immunol Immunopathol. 1994;71:113–20.
Stadlmayr W, Spitzweg C, Bichlmair AM, Heufelder AE. TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves’ ophthalmopathy and pretibial myxedema. Thyroid. 1997;7:3–12.
Daumerie C, Ludgate M, Costagliola S, Many MC. Evidence for thyrotropin receptor immunoreactivity in pretibial connective tissue from patients with thyroid-associated dermopathy. Eur J Endocrinol. 2002;146:35–8.
Heufelder AE, Dutton CM, Sarkar G, Donovan KA, Bahn RS. Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves’ ophthalmopathy and pretibial dermopathy. Thyroid. 1993;3:297–300.
Shishiba Y, Tanaka T, Ozawa Y, Shimizu T, Kadowaki N. Chemical characterization of high buoyant density proteoglycan accumulated in the affected skin of pretibial myxedema of Graves’ disease. Endocrinol Jpn. 1986;33:395–403.
Bahn RS. The fibroblast is the target cell in the connective tissue manifestations of Graves’ disease. Int Arch Allergy Immunol. 1995;106:213–8.
Gianoukakis AG, Jennings TA, King CS, Sheehan CE, Hoa N, Heldin P, Smith TJ. Hyaluronan accumulation in thyroid tissue: evidence for contributions from epithelial cells and fibroblasts. Endocrinology. 2007;148:54–62.
Bahn RS, Smith TJ, Gorman CA. The central role of the fibroblast in the pathogenesis of extrathyroidal manifestations of Graves’ disease. Acta Endocrinol Suppl. 1989;121:75–81.
Wortsman J, Dietrich J, Traycoff RB, Stone S. Preradial myxedema in thyroid disease. Arch Dermatol. 1981;117:635–8.
Ishii M, Nakagawa K, Hamada T. An ultrastructural study of pretibial myxedema utilizing improved ruthenium red stain. J Cutan Pathol. 1984;11:125–31.
Matsuoka LY, Wortsman J, Uitto J, Hashimoto K, Kupchella CE, Eng AM, Dietrich JE. Altered skin elastic fibers in hypothyroid myxedema and pretibial myxedema. Arch Intern Med. 1985;145:117–21.
Salvi M, De Chiara F, Gardini E, Minelli R, Bianconi L, Alinovi A, Ricci R, Neri F, Tosi C, Roti E. Echographic diagnosis of pretibial myxedema in patients with autoimmune thyroid disease. Eur J Endocrinol. 1994;131:113–9.
Peacey SR, Flemming L, Messenger A, Weetman AP. Is Graves’ dermopathy a generalized disorder? Thyroid. 1996;6:41–5.
Sage RD, Farber EM. Pretibial myxedema; presentation of a case initiated by trauma. Stanford Med Bull. 1958;16:28–31.
Singh SP, Ellyin F, Singh SK, Yoon B. Case report: Elephantiasis-like appearance of upper and lower extremities in Graves' dermopathy. Am J Med Sci. 1985;290:73–6.
Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr Rev. 2003;24:802–35.
Smith TJ. Fibroblast biology in thyroid diseases. Curr Opin Endocrinol Diabetes. 2002;9:393–400.
Rapoport B, Alsabeh R, Aftergood D, et al. Elephantiasic pretibial myxedema: insights into and a hypothesis regarding the pathogenesis of extrathyroidal manifestations of Graves’ disease. Thyroid. 2000;10:685–92.
Schwartz KM, Ahmed DD, Ahmed I, et al. Development of localized myxedema in a skin graft. Int J Dermatol. 2002;41:401–3.
Missner SC, Ramsay EW, Houck HE, Kauffman CL. Graves’ disease presenting as localized myxedema in a thigh donor graft site. J Am Acad Dermatol. 1998;39:846–9.
Hasani-Ranjbar S, Mohajeri-Tehrani MR. Localized myxedema of the toe: a rare presentation of graves’ dermopathy. Arch Iran Med. 2008;11:326–9.
Katsambas A, Pantazi V, Giannakopoulou H, Potouridou I. Localized myxedema in Grave’s disease confined to the toes. Int J Dermatol. 2000;39:953–4.
Chang A, Hsieh AT. Localized myxedema of the foot: a rare presentation of graves’ dermopathy. J Exp Clin Med. 2013;5:124–5.
Siegler M, Retetoff S. Pretibial myxedema: a reversible cause of foot drop due to entrapment of the peroneal nerve. N Engl J Med. 1976;294:1383–4.
Gitter DG, Sato K. Localized hyperhidrosis in pretibial myxedema. J Am Acad Dermatol. 1990;23:250–4.
Tatnall FM, Sarkany I. Profuse hyperhidrosis localized to pretibial myxedema. Br J Dermatol. 1985;113:65–6.
Kato N, Ueno H, Matsubara M. A case report of EMO syndrome showing localized hyperhidrosis in pretibial myxedema. J Dermatol. 1991;18:598–604.
Albers SE, Fenske NA. Exuberant tumoral lesions on the dorsum of the foot. Pretibial myxedema. Arch Dermatol. 1991;127(247–248):250–41.
Shiraishi T, Hanami Y, Oyama N, Yamamoto T. A case of nodular pretibial myxedema. J Dermatol. 2010;37:106.
Chen YM, Chen HH, Lan JL, Chen DY, Sheu WH. Nodular mucinosis in Graves disease mimicking gouty tophi. J Clin Rheumatol. 2010;16:287–9.
Hunzeker CM, Kamino H, Walters RF, Kovich OI. Nodular pretibial myxedema. Dermatol Online J. 2008;14:8.
Gopie P, Naraynsingh V. Severe pretibial myxedema. Int J Low Extrem Wounds. 2011;10:91–2.
Wright AL, Buxton PK, Menzies D. Pretibial myxedema localized to scar tissue. Int J Dermatol. 1990;29:54–5.
Forgie JC, Highet AS, Kelly SA. Myxoedematous infiltrate of the forehead in treated hypothyroidism. Clin Exp Dermatol. 1994;19:168–9.
Kim BJ, Kazim M. Prominent premalar and cheek swelling: a sign of thyroid-associated orbitopathy. Ophthal Plast Reconstr Surg. 2006;22:457–60.
Bilen H, Atasoy M, Akcay G, Akcay M, Capoglu I, Gursan N, Akbas M. Elephantiasic pretibial myxedema and cutis verticis gyrata caused by Graves’ disease. Thyroid. 2006;16:815–6.
Takahashi Y, Nakagawa Y, Fujishima F, Mori K. A swollen index finger as a presentation of thyroid dermopathy. Intern Med. 2010;49:1831.
Ogrin C. Increased bone alkaline phosphatase and isolated subcortical bone uptake of technetium-99 m hydroxymethylene diphosphonate in the lower extremities in a patient with Graves’ disease: a distinctly unusual variant of Graves’ acropachy. Thyroid. 2008;18:1227–9.
Ekmekci TR, Ucak S, Sakiz D, Bankaoglu M, Koslu A, Altuntas Y. Investigation of the presence of acropachy in patients with autoimmune thyroid diseases. Endocrinologist. 2007;17:23–5.
Shih SR, Lin MS, Li HY, Yang HY, Hsiao YL, Chang MT, Chen CM, Chang TC. Observing pretibial myxedema in patients with Graves' disease using digital infrared thermal imaging and high-resolution ultrasonography: for better records, early detection, and further investigation. Eur J Endocrinol. 2011;164:605–11.
Matsuoka LY, Wortsman J, Carlisle KS, Kupchella CK, Dietrich JG. The acquired cutaneous mucinoses. Arch Intern Med. 1984;144:1974–80.
Alvarez-Garrido H, Najera L, Garrido-Rios AA, Cordoba-Guijarro S, Huerta-Brogeras M, Aguado-Lobo M, Borbujo J (2014) Acral persistent papular mucinosis: Is it an under-diagnosed disease? Dermatology Online J 20: pii: doj_21757
Shlyankevich J, George E, Stetsenko G, Vary Jr J. Granulomatous variant of scleromyxedema mimicking a drug reaction. J Am Acad Dermatol. 2013;1:AB86.
Wang P, Yang HJ, Ran YP. Localized papular mucinosis with IgA nephropathy a case report. Arch Dermatol. 2011;147:599–602.
Kerns MJ, Mutasim DF. Focal cutaneous mucinosis in Graves disease: relation to pretibial myxedema. Am J Dermatopathol. 2010;32:196–7.
Rongioletti F, Donati P, Amantea A, Ferrara G, Montinari M, Santoro F, Parodi A. Obesity-associated lymphoedematous mucinosis. J Cutan Pathol. 2009;36:1089–94.
Kim KJ, Kim HH, Chang SE, Choi JH, Sung KJ, Moon KC, Koh JK. A case of pretibial mucinosis without thyroid disease. J Dermatol. 2002;29:383–5.
Jackson EM, English IJC. Diffuse cutaneous mucinoses. Dermatol Clin. 2002;20:493–501.
Mir M, Jogi R, Rosen T. Pretibial mucinosis in a patient without Graves disease. Cutis. 2011;88:300–2.
Somach SC, Helm TN, Lawlor KB, Bergfeld WF, Bass J. Pretibial mucin. Histologic patterns and clinical correlation. Archives of dermatology. 1993;129:1152–6.
Volke V, Matjus S. Unilateral pitting edema of leg as a manifestation of Graves’ disease: a case report. J Med Case Rep. 2012;6:258.
Hiroi N, Sakamoto Y, Urita Y, Higa M, Kuboki K, Yoshino G. Graves’ disease with intractable diarrhea, chylous ascites, and chylothorax: a case report. Thyroid. 2007;16:1299–303.
Pineda C, Martinez-Lavin M. Hypertrophic osteoarthropathy: what a rheumatologist should know about this uncommon condition. Rheum Dis Clin North Am. 2013;39:383–400.
Batal O, Hatem SF. Radiologic case study. Thyroid Acropachy Orthopedics. 2008;31(2):98–100.
Seigel RS, Thrall JH, Sisson JC. 99mTc-pyrophosphate scan and radiographic correlation in thyroid acropachy: case report. J Nucl Med. 1976;17:791–3.
Parker LN, Wu SY, Lai MK, Ramadan MB, Rajan RK, Yusi AM. The early diagnosis of atypical thyroid acropachy. Arch Intern Med. 1982;142:1749–51.
Vanhoenacker FM, Pelckmans MC, De Beuckeleer LH, Colpaert CG, De Schepper AM. Thyroid acropachy: correlation of imaging and pathology. Eur Radiol. 2001;11:1058–62.
King LR. A case study of peculiar soft tissue and bony changes in association with thyroid disease. J Clin Endocrinol Metab. 1959;19:1323–30.
Wiersinga WM. Graves' orbitopathy: management of difficult cases. Ind J Endocrinol Metab. 2012;16:S150–2.
Stan MN, Bahn RS. Risk factors for development or deterioration of Graves’ ophthalmopathy. Thyroid. 2010;20:777–83.
Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab. 2007;92:59–64.
Hegedus L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves' ophthalmopathy. J Endocrinol Invest. 2004;27:265–71.
Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM, European Group on Graves O. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158:273–85.
Stan MN, Duraski JM, Brito JP, Bhagra S, Thapa P, Bahn RS. Cohort study on radioactive iodine -induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid. 2013;23:620–5.
Bartalena L, Marccocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves ophthalmopathy after radioiodine therapy of hyperthyroidism. N Engl J Med. 1989;321:1349–52.
Bartalena L. Prevention of Graves’ ophthalmopathy. Best Pract Res Clin Endocrinol Metab. 2012;26:371–9.
Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Del’Uno E, Bruno-Bossio G, Nardi M, Bartolomei MP, Leprii A, Rossi G, Pinchera A. Relation between therapy for hyperthyroidism and the course of graves’ ophthalmopathy. N Engl J Med. 1998;338:73–8.
Lauerberg P, Wallin G, Tallstedt L, Abraham-Nording M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves' disease after therapy with antithyroid drugs, surgery, or radioactive iodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158:69–75.
Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab. 2010;95:1333–7.
Moleti M, Mattina F, Salamone I, Violi MA, Nucera C, Baldari S, Lo Schiavo MG, Regalbuto C, Trimarchi F, Vermiglio F. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of Graves’ ophthalmopathy. Thyroid. 2003;13:653–8.
Bahn RS, Burch HB, Cooper DS, Greenlee MC, et al. Hyperthyroidism and other causes of thyrotoxicosis; management guidelines of the american thyroid Association and american association of clinical endocrinologists. Endocr Pract. 2011;17:456–520.
Stan MN, Garrity JA, Bahn RS. The evaluation and treatment of graves ophthalmopathy. Med Clin North Am. 2012;96:311–28.
Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W, European Group on Graves O. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011;364:1920–31.
Chiovato L, Latrota LE, Braverman LE, Pacini F, Capezzonie M, Masserini L, Grasso l, Grasso l. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigen. Ann Intern med. 2003;139:246–51.
Moleti M, Violo MA, Montanini D, Trombetta C, Di Bella B, Sturniolo G, Presti S, Alibrandi A, Campenni A, Baldari S, Trimarchi F, Vermiglio F. Radioiodine ablation of postsurgical thyroid remnants after treatment with recombinant human TSH(rhTSH) in patients with moderate-to-severe Graves' orbitopathy (GO): a prospective, randomized, single-blind clinical trial. J Clin Endocrinol Metab. 2014;99:1783–99. 20133093. [EPub ahead of print].
Nwatsock JF, Taieb D, Tessonnier L, Mancini J, Dong AZF, Mundler O. Radioiodine thyroid ablation in graves’ hyperthyroidism: merits and pitfalls. World J Nucl Med. 2012;11:7–11.
Leo M, Marcocci C, Pinchera A, Nardi M, Megna L, Rocchi R, Latrofa F, Altea MA, Mazzi B, Sisti E, Profilo MA, Marino M. Outcome of Graves’ orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab. 2012;97:E44–8.
Leslie WS, Hankey CR, Lean MEJ. Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM. 2007;100:395–404.
Tokuda Y, Kawachi S, Murata H, Saida T. Chronic obesity lymphoedematous mucinosis: three cases of pretibial mucinosis in obese patients with pitting oedema. Br J Dermatol. 2006;154:157–61.
Kriss JP, Pleshakov V, Rosenblum A, Sharp G. Therapy with occlusive dressings of pretibial myxedema with fluocinolone acetonide. J Clin Endocrinol Metab. 1967;27:595–604.
Kriss JP. Pathogenesis and treatment of pretibial myxedema. Endocrinol Metab Clin North Am. 1987;16:409–15.
Takasu N, Higa H, Kinjou Y. Treatment of pretibial myxedema (PTM) with topical steroid ointment application with sealing cover (steroid occlusive dressing technique: steroid ODT) in Graves’ patients. Intern Med. 2010;49:665–9.
Susser WS, Heermans AG, Chapman MS, Baughman RD. Elephantiasic pretibial myxedema :a novel treatment for an uncommon disorder. J Am Acad Dermatol. 2002;46:723–6.
Bernardi JM, Malone J. Thyroid dermopathy localized to areas of injury and responsive to complete decongestive physiotherapy. J Am Acad Dermatol. 2011;64:1219–20.
Verma S, Rongioletti F, Braun-Falco M, Ruzicka T. Preradial myxedema in a euthyroid male: a distinct rarity. Dermatol Online J. 2013;19:9.
Pingsmann A, Ockenfels HM, Patsalis T. Surgical excision of pseudotumorous pretibial myxedema. Foot Ankle Int. 1996;17:107–10.
Lang PG, Sisson JC, Lynch PJ. Intralesional triamcinolone therapy for pretibial myxedema. Arch Dermatol. 1975;111:197–202.
Deng A, Song D. Multipoint subcutaneous injection of long-acting glucocorticoid as a cure for pretibial myxedema. Thyroid. 2011;21:83–5.
Vannucchi G, Campi I, Covelli D, Forzenigo L, Beck-Peccoz P, Salvi M. Treatment of pretibial myxedema with dexamethasone injected subcutaneously by mesotherapy needles. Thyroid. 2013;23:626–32.
Zang S, Ponto KA, Kahaly GJ. Intravenous glucocorticoids for graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metabol. 2011;96:320–32.
Rotman-Pikielny P, Brucker-Davis F, Turner ML, Sarlis NJ, Skarulis MC. Lack of effect of long-term octreotide therapy in severe thyroid-associated dermopathy. Thyroid. 2003;13:465–70.
Stan MN, Garrity JA, Bradley EA, Woog JJ, Bahn MM, Brennan MD, Bryant SC, Achenbach SJ, Bahn RS. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2006;91:4817–24.
Dickinson AJ, Vaidya B, Miller M, Coulthard A, Perros P, Baister E, Andrews CD, Hesse L, Heverhagen JT, Heufelder AE, Kendall-Taylor P. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2004;89:5910–5.
Noppen M, Velkeniers B, Steenssens L, Vanhaelst L. Beneficial effects of plasmapheresis followed by immunosuppressive therapy in pretibial myxedema. Acta Clin Belg. 1988;43:381–3.
Kuzuya N, DeGroot LJ. Effect of plasmapheresis and steroid treatment on thyrotropin binding inhibitory immunoglobulins in a patient with exophthalmos and a patient with pretibial myxedema. J Endocrinol Invest. 1982;5:373–8.
Dandona P, Marshall NJ, Bidey SP, Nathan A, Havard CW. Successful treatment of exophthalmos and pretibial myxoedema with plasmapheresis. Br Med J. 1979;1:374–6.
Kriss JP. Treatment of exophthalmos and pretibial myxoedema with plasmapheresis. Br Med J. 1979;1:1149–50.
Dhaille F, Dadban A, Meziane L, Fessier C, Colta L, Lok C, Chaby G. Elephantiasic pretibial myxoedema with upper-limb involvement, treated with low-dose intravenous immunoglobulins. Clin Exp Dermatol. 2012;37:307–8.
Antonelli A, Navaranne A, Palla R, Alberti B, Saracino A, Mestre C, Roger P, Agostini S, Baschieri L. Pretibial myxedema and high dose intravenous immunoglobulin. Thyroid. 1994;4:399–408.
Keith P, Pittelkow M. Spontaneous resolution of Graves pretibial myxedema: a review of Graves dermopathy, associated autoantibody tests, and new treatment modalities. J Am Acad Dermatol. 2014;1:AB119.
Heyes C, Nolan R, Leahy M, Gebauer K. Treatment-resistant elephantiasic thyroid dermopathy responding to rituximab and plasmapheresis. Australas J Dermatol. 2012;53:e1–4.
Kumar S, Iyer S, Bauer H, Coenen MJ, Bahn RS. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves' orbital fibroblasts: inhibition by an IGF-1 receptor blocking antibody. J Clin Endocrinol Metab. 2012;97:1681–7.
Perziale N, Kovacs SC, Thomas CB, Srinvasan J. Rituximab and mycophenolate combination therapy in refractory dermatomyositis with multiple autoimmune disorders. J Clin Neuromuscul Disease. 2011;13:63–7.
Levy JM, Hasney CP, Freidlnder PL, Kandil E, Occhipinti EA, kahn MJ. Combined mycophenolate mofetil and prednisone therapy in tamoxifen- and prednisone-resistant Reidel's thyroiditis. Thyroid. 2010;20:105–7.
Turcu AF, Kumar S, Neumann S, Coenen M, Iyer S, Chiriboga P, Gershengorn MC, Bahn RS. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab. 2013;98:2153–9.
Bahn RS. Autoimmunity and Graves’ disease. Clinical Pharmacol Ther. 2012;91:577–9.
Botta R, Lisi S, Marcocci C, Sellari-Franceschini S, Rocchi R, Latrofa F, Menconi F, Altea MA, Leo M, Sisti E, Casini G, Nardi M, Pinchera A, Vitti P, Marino M. Enalapril reduces proliferation and hyaluronic acid release in orbital fibroblasts. Thyroid. 2013;23:92–6.
Zhang C, Zhang X, Ma L, Peng F, Huang J, Han H. Thalidomide inhibits adipogenesis of orbital fibroblasts in Graves’ ophthalmopathy. Endocrine. 2012;41:248–55.
Issafiras H, Corbin JA, Goldfine ID, Roell MK. Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-beta antibody with differential receptor-modulating properties. J Pharmacol Exp Ther. 2014;348:202–15.
Runkle L, Stacey J. Lupus clinical development: will belimumab’s approval catalyses a new paradigm for SLE drug development. Expert Opin Biol Ther. 2014;14:491–501.
McCluggage LK. Safety of TNF inhibitors in adolescents and children. Adolesc Health Med Ther. 2010;32:1–8.
Michalova K, Lim L. Biologic agents in the management of inflammatory eye diseases. Curr Allergy Asthma Rep. 2008;8:339–47.
Bonafoux D, Lee WC. Strategies for TGF-beta modulation: a review of recent patents. Expert Opin Ther Pat. 2009;19:1759–69.
Tanaka T, Narazaki M. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol. 2014;26:88–96.
Carruth BP, Wladis EJ. Inflammatory modulators and biologic agents in the treatment of idiopathic orbital inflammation. Curr Opin Ophthalmol. 2012;23:420–6.
Rajasekaran S, Kruse K, Kovey K, Davis AT, Hassan NE, Ndika AN, Zuiderveen S, Birmingham J. Therapeutic role of Anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction/macrophage activating syndrome in critically ill children. Pediatr Crit Care Med. 2014;15:401–8.
Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye (Lond). 2005;19:1286–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Fatourechi, V. (2015). Thyroid Dermopathy and Acropachy. In: Bahn, R. (eds) Graves' Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2534-6_15
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2534-6_15
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-2533-9
Online ISBN: 978-1-4939-2534-6
eBook Packages: MedicineMedicine (R0)